Michael Fisch

The University of Texas MD Anderson Cancer Center

Also affiliated with Eye Care Associates

MedicineEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain”.

Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.41720

N/A

1.5DataRank · unranked

56 citations

Joseph M. Unger, Heather Greenlee, Jillian L. Capodice, Danika L. Lew, Amy K. Darke +5 more

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12018

N/A

0DataRank · unranked

2 citations

Joseph M. Unger, Heather Greenlee, Jillian L. Capodice, Danika L. Lew, Amy K. Darke +5 more

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12003

N/A

0DataRank · unranked

2 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

Socioeconomic deprivation and patient-reported outcomes in symptom management trials for patients with breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.28_suppl.158

N/A

0DataRank · unranked

2 citations

Cathee Till, N. Lynn Henry, Michael Fisch, Dawn L. Hershman, Joseph M. Unger +1 more

Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12094

N/A

0DataRank · unranked

0 citations

John Devin Peipert, Vered Stearns, Victor T. Chang, Opeyemi A. Jegede, Edward H. Ip +15 more

Trends in low-value oncology care during the COVID-19 pandemic.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6594

N/A

0DataRank · unranked

0 citations

Yasin Civelek, Pelin Ozluk, David Debono, Michael Fisch, Gosia Sylwestrzak +3 more

Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12024

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Dawn L. Hershman, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan +8 more

Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12003

N/A

0DataRank · unranked

11 citations

Joseph M. Unger, Dawn L. Hershman, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan +9 more

Examining uptake of electronic patient reported outcomes (ePRO) in a prospective study of immune-related adverse events (IR-AEs).

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.368

N/A

0DataRank · unranked

2 citations

Amy K. Darke, Krishna S. Gunturu, Dawn L. Hershman, Michael Fisch, N. Lynn Henry +2 more

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Journal of Patient-Reported Outcomes(2020)10.1186/s41687-020-00220-x

N/A

0DataRank · unranked

5 citations

Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries +15 more

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2137

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more